About Hybrigenics
Overview
Strategy
Management
Management Team
Board Of Directors
Investors Relations
Videos Corner
Decideurs TV
Film Corporate
Shares Informations
Press Releases
Documentations
Shareholders & GM
Subscribe Mailing List
Investors Contacts
Infos - Médias
Careers
Contact Us
Overview
Go to dedicated site
Home
Our Involvement
Therapeutic Focus
R&D Pipeline
Research
Our Programs
Proteases Program
Our Collaboration
Our Partners
Publications
Inecalcitol Development
Product Profile
Prostate Cancer
Clinical Trials
Other Indications
Psoriasis
Hyperparathyroidism
Partnering
News
Overview
Go to dedicated site
Home
Our Expertise
About us
Why Protein Interactions?
Y2H Principle
Our Services
Our Teams
Protein Interaction Maps
DISCOVER Interactions
ULTImate Y2H™
Offer
Key Advantages
Screen Process
Deliverables
Libraries
Libraries List
Bioinformatic Tools
PIMRider®
DomSight®
Associated Services
Y2H +1
1-by-1 Y2H
1-by-1 HTRF®
Bait Cloning
VALIDATE Interactions
Domain Mapping
Loss of Affinity Mutants
Cloning-Subcloning
Protein Production
INHIBIT Interactions
Compound Libraries
Diversity Library
Natural Compounds
Assay Development & Screening
HTRF®
Permeable Y2H
Fluorescence Polarization
HTS
Compound Evaluation
References
Satisfaction
Testimonials
ISO 9001
Publications
Order
How To
Prices
Your Contact Information
Distributors
News
Where to meet us
Newsletter EXPERTISE
Contact Us
WELCOME
HYBRIGENICS IS DEDICATED
TO DEVELOP INNOVATIVE
DRUGS
TO FIGHT
CANCER
AND TO PROVIDE EXPERT
SERVICES
IN
PROTEIN
INTERACTIONS
BY SHARING
THE SAME TRUST IN
SCIENCE FOR LIFE
Hybrigenics unveils a lead chemical structure for its discovery of new anticancer drugs
Hybrigenics receives authorization
to dose prostate cancer patients
twice daily with oral inecalcitol
2009 Turnover and Revenues:
Growth of +15%
Improved Cash Position to sustain R&D projects
Investors
Contact Us
Glossary
Site Map
Legal Mentions
English
Français
© 2010 hybrigenics
